Gilles estimates a growth rate of 8-10% for our basic business. This could mean a turnover of 20 million for 2022. The profit from this could amount to around 5 million, approx. 6.5c per share. With a PER of 15, this equates to a price target of $ 1 alone. The discussion about the BG pill is too early, results will not be available until the end of 2021. PGX is the topic that is currently pending. All market participants are very nervous at the moment - nobody is informed about the current situation. Therefore - waiting for quarterly results and then commenting - makes more sense.